E
Exogenesis
Exogenesis Corporation is engaged in developing and processing implantable vascular stents, orthopedic devices and other related products
About Exogenesis
Exogenesis Corporation specializes in nanoscale surface modification technology, primarily targeting the medical device industry. The company collaborates with partners for research and commercialization of its proprietary technology, which enhances the surface properties of medical implants. Exogenesis operates in the healthcare market, focusing on improving the biocompatibility and performance of medical devices such as hernia meshes and spinal interbody fusion devices. The business model revolves around licensing its technology and forming strategic partnerships for product development and commercialization. Revenue is generated through licensing fees, research collaborations, and product sales.
Source: Dealroom company dataAt a glance
- Founded
- 2005
- Headquarters
- Billerica, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- VEVenture Capital Fund of New England
- IVInflectionPoint Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exogenesis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exogenesis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.